Liver steatosis is the medical term for excess fat stored inside liver cells. A healthy liver contains some fat, but when fat makes up more than about 5% of the liver’s weight, the organ crosses into steatosis territory. The condition is remarkably common, driven primarily by metabolic factors like obesity, insulin resistance, and diet, and it ranges from a mild, reversible buildup to a gateway for serious liver damage. Understanding what the grades mean, how doctors detect it, and where the real risks lie can help you make sense of a diagnosis that millions of people receive every year.
Why the Name Keeps Changing
If you’ve seen both “NAFLD” and “MASLD” floating around, you’re not imagining things. For decades, the umbrella term was non-alcoholic fatty liver disease (NAFLD), defined mainly by what it wasn’t: fatty liver not caused by heavy drinking. In 2023, an international consensus replaced that label with metabolic dysfunction-associated steatotic liver disease (MASLD), which defines the condition by what it is: fatty liver tied to at least one metabolic risk factor such as excess body weight, elevated blood sugar, high blood pressure, or abnormal blood lipids. Over 95% of people previously diagnosed with NAFLD meet the criteria for MASLD, so for most patients the condition itself hasn’t changed, just the name on the chart.1PubMed Central. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease The new framework also created a category called MetALD for people whose fatty liver involves both metabolic dysfunction and higher-than-moderate alcohol intake. Throughout this article, the older and newer terms may appear interchangeably because most of the published research still uses NAFLD.
How Fat Accumulates in the Liver
Your liver is constantly juggling fat. It takes in fatty acids from the bloodstream and builds new fat molecules through a process called de novo lipogenesis. It also burns fat for energy and exports it packaged into lipoproteins that travel to other tissues. Steatosis develops when the intake-and-production side outpaces the burning-and-exporting side.2PubMed Central. Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease In people with metabolic risk factors, two things tend to go wrong at once: the liver absorbs more fatty acids than normal (often because insulin resistance causes fat tissue to release excess free fatty acids into the blood), and it ramps up internal fat production. The liver tries to compensate by burning more fat, but that compensatory effort isn’t enough to clear the surplus. Worse, ramped-up fat burning can itself generate oxidative stress, which damages liver cells and nudges the disease forward.
Dietary fructose deserves special mention here. Unlike glucose, fructose arrives at the liver in high concentrations via the portal vein and doesn’t need insulin to be metabolized. It directly stimulates the molecular machinery for fat production more potently than a high-fat diet does, making sugary drinks and processed foods with added fructose a particularly efficient way to feed liver fat.3PubMed Central. Role of Dietary Fructose and Hepatic De Novo Lipogenesis in Fatty Liver Disease
What the Grades Mean
Doctors grade steatosis by estimating how much of the liver tissue is filled with fat droplets. The most widely used histological scoring system assigns a steatosis grade from S0 to S3, where S0 means less than 5% of liver cells contain visible fat and essentially represents a normal liver. The threshold for a diagnosis is 5% or more of hepatocytes showing fat accumulation.4PubMed. Pathology of non-alcoholic fatty liver disease
- S1 (mild): roughly 5% to 33% of liver cells affected.
- S2 (moderate): roughly 34% to 66% of liver cells affected.
- S3 (severe): more than 66% of liver cells affected.
The steatosis grade tells you how much fat is present but says nothing on its own about inflammation or scarring. That’s why pathologists also assess an activity score (grading inflammation and cell ballooning) and a fibrosis stage (F0 through F4), together forming the SAF score. You can have S3 steatosis with zero fibrosis, which is concerning but far more treatable than S1 steatosis paired with F3 fibrosis. In practical terms, the fibrosis stage matters more for your long-term outlook than the fat grade alone.
How Steatosis Is Detected
Most people learn they have a fatty liver incidentally, after an abdominal ultrasound ordered for some other reason picks up a bright, echogenic liver. Standard ultrasound is inexpensive and widely available, but it struggles to detect steatosis when less than about 20–30% of liver cells are affected, and it cannot reliably distinguish moderate from severe grades.
For more precise fat measurement, MRI-based techniques are the current gold standard. A method called MRI proton density fat fraction (MRI-PDFF) directly quantifies the percentage of fat in liver tissue and significantly outperforms ultrasound-based tools at grading steatosis, particularly at higher grades.5PubMed Central. Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates One head-to-head comparison found that MRI-based imaging had near-perfect accuracy for detecting any steatosis, while an ultrasound-based tool called controlled attenuation parameter (CAP) performed well for detecting the presence of fat but fell off considerably when trying to distinguish moderate from severe grades.6PLOS ONE. Comparison between magnetic resonance and ultrasound-derived indicators of hepatic steatosis in a pooled NAFLD cohort MRI is more expensive and less accessible, though, so it tends to be reserved for clinical trials and cases where precise fat quantification changes management decisions.
Because the fibrosis stage drives prognosis more than the fat grade, doctors also use simple blood-based scores to estimate scarring risk. The FIB-4 index, calculated from your age, platelet count, and two liver enzymes, can satisfactorily flag advanced fibrosis and works as a first-pass screening tool in primary care.7PubMed Central. Diagnostic role of the fibrosis-4 index and nonalcoholic fatty liver disease fibrosis score as a noninvasive tool for liver fibrosis scoring A low FIB-4 score is reassuring; a high one prompts further testing with elastography or biopsy. For people with type 2 diabetes, who carry higher baseline liver risk, applying age-adjusted FIB-4 cutoffs helps avoid overwhelming hepatology clinics with unnecessary referrals.8BMJ Open Diabetes Research & Care. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications
From Simple Fat to Serious Damage
Simple steatosis on its own is generally considered the mildest form of the disease. Many people stay at this stage for years without progressing. The danger comes when fat accumulation triggers persistent inflammation and liver cell injury, a stage called metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). From there, the liver can develop fibrosis, and fibrosis can advance through stages toward cirrhosis.9PubMed. DNA Methylation and Target Gene Expression in Fatty Liver Progression From Simple Steatosis to Advanced Fibrosis
The pace of progression varies widely between individuals. Real-world data from a large registry show that the risk of progressing to cirrhosis climbs steeply with fibrosis stage. Compared to people with F0 or F1 fibrosis, those already at F3 had a roughly 19-fold higher risk of developing cirrhosis, while those at F2 had about a four-fold higher risk.10PubMed Central. Understanding MASH: An Examination of Progression and Clinical Outcomes by Disease Severity in the TARGET-NASH Database Among patients who did progress to serious outcomes, about two-thirds had type 2 diabetes and nearly three-quarters had hypertension, reinforcing how tightly metabolic health and liver disease are linked.
Liver cancer is another endpoint worth knowing about. While the cancer risk is substantially higher once cirrhosis is established, roughly 38% of fatty-liver-related liver cancers are diagnosed in people who have not yet developed cirrhosis.11PubMed Central. Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis That statistic challenges the old assumption that you only need to worry about liver cancer after cirrhosis has set in.
Risks Beyond the Liver
The leading cause of death in people with fatty liver disease is not liver failure. It’s cardiovascular disease. A fatty liver pumps out inflammatory signals and abnormal lipoproteins that accelerate atherosclerosis throughout the body. One study found that fatty liver disease was an independent predictor of cardiovascular events even after accounting for the usual risk factors like high cholesterol and high blood pressure, with roughly a fourfold increase in odds.12PubMed Central. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease
The relationship between fatty liver and type 2 diabetes is bidirectional. Insulin resistance drives fat into the liver, and the fat-laden liver in turn worsens insulin resistance by impairing glucose handling, creating a feedback loop that accelerates both conditions.13PubMed Central. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship Shared pathways including chronic low-grade inflammation and altered gut-derived signals help explain why treating one condition often improves the other.14PubMed Central. Metabolic dysfunction associated fatty liver disease and type 2 diabetes: pathophysiological links, epidemiological trends, and clinical implications
Genetic Susceptibility
Not everyone with obesity or metabolic syndrome develops fatty liver, and some lean people do. Genetics partly explains why. The most important gene identified so far is PNPLA3. A variant called I148M (rs738409) is strongly associated with increased liver fat levels, and people who carry two copies of this variant have more than twice the hepatic fat of noncarriers.15Nature Genetics. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease The variant is most common in people of Hispanic ancestry, which tracks with the higher rates of fatty liver disease observed in that population. A pooled analysis of 35 studies confirmed that carrying two copies of the risk allele roughly quadrupled the odds of developing steatohepatitis compared to noncarriers.16PubMed Central. PNPLA3 as a Genetic Determinant of Risk for and Severity of Non-alcoholic Fatty Liver Disease Spectrum
A second gene, TM6SF2, has also been linked to fatty liver susceptibility across multiple large populations. Its variant, E167K, is associated with higher degrees of steatosis, inflammation, and fibrosis after adjusting for other risk factors like body weight and diabetes status.17Gastroenterology. What Is Liver Steatosis? Fat Buildup, Grades & Risks Neither variant alone determines whether you develop fatty liver; they raise the baseline risk, which lifestyle and metabolic factors then amplify or mitigate.
Weight Loss and Exercise
Weight loss remains the most effective intervention for reversing steatosis. The evidence is dose-dependent: losing at least 5% of your body weight meaningfully reduces liver fat and inflammation markers, while losing 10% or more leads to resolution of steatohepatitis in about 90% of people and regression of fibrosis in nearly half.18PubMed Central. Nonalcoholic Fatty Liver Disease and Obesity Treatment The catch is that only about one in ten participants in clinical trials actually achieves 10% weight loss and sustains it, making that target aspirational for many.
Exercise helps even without weight loss. A meta-analysis of trials found that aerobic exercise alone reduced liver fat content, and a combination of aerobic and resistance training did too, independent of changes on the scale.19PubMed Central. Positive Effects of Exercise Intervention without Weight Loss and Dietary Changes in NAFLD-Related Clinical Parameters: A Systematic Review and Meta-Analysis A trial directly comparing the two exercise types found that both aerobic and resistance training reduced hepatic fat and improved liver enzyme levels to a similar degree, with the aerobic group achieving these benefits independent of weight change.20PubMed Central. Effect of Aerobic and Resistance Exercise Training on Liver Enzymes and Hepatic Fat in Iranian Men With Nonalcoholic Fatty Liver Disease The practical takeaway: pick whatever form of exercise you’ll actually stick with.
Emerging Drug Treatments
For decades there was no approved medication specifically for fatty liver disease. That changed in 2024 when resmetirom, a thyroid hormone receptor agonist, became the first drug approved in the United States for adults with MASH and moderate to advanced fibrosis. Resmetirom works by activating a liver-specific thyroid receptor that increases fat burning and clearance within liver cells. In preclinical models, it significantly improved steatosis scores and reduced markers of liver scarring.21PubMed Central. Differences between therapeutic mechanisms of resmetirom and semaglutide against MASH in western diet-fed MC4R-knockout mice
GLP-1 receptor agonists like semaglutide, already widely used for type 2 diabetes and weight management, also show promise. In animal models, semaglutide reduced disease activity scores and significantly decreased fibrosis markers, though through different mechanisms than resmetirom, primarily by reducing body weight and improving metabolic signaling.22Exploration of Endocrine and Metabolic Diseases. Comparative pharmacodynamic analysis of resmetirom, semaglutide and obeticholic acid in translational mouse models of MASH Human trials are ongoing, and the prospect of combining drugs with different mechanisms is generating considerable interest in hepatology.
The Gut Connection
Your gut and liver share a direct highway: the portal vein carries blood from the intestines straight to the liver, bringing along whatever the gut lining lets through. When the community of bacteria in your gut falls out of balance, the intestinal barrier can weaken, allowing bacterial products like endotoxins to leak into the portal bloodstream. Those toxins trigger inflammatory responses in the liver, worsen insulin resistance, and promote fibrosis.23PubMed Central. Gut microbiota and metabolic-associated steatosis liver disease: Unveiling mechanisms and opportunities for therapeutic intervention High-fat diets and heavy alcohol intake are among the environmental factors that can shift gut microbial communities toward a state that promotes liver disease.24Nature Reviews Microbiology. The gut–liver axis and gut microbiota in health and liver disease Research into whether targeted probiotics or microbiome-modulating therapies can meaningfully reverse steatosis is still in early stages, but the gut-liver axis is one of the more active areas of investigation.
Children and Fatty Liver
Fatty liver is not an adults-only problem. MASLD is now the most common reason for elevated liver enzymes in children in Europe, affecting more than 5% of all children.25PubMed Central. European Society for Pediatric Gastroenterology, Hepatology and Nutrition steatotic liver disease special interest group position paper on screening, diagnosis and investigation of paediatric metabolic dysfunction‐associated steatotic liver disease Childhood obesity is the primary driver, and the same metabolic risk factors seen in adults, including insulin resistance and dyslipidemia, apply to kids. The concern with pediatric cases is the long runway of disease: a child diagnosed at age 10 has decades of potential progression ahead, making early lifestyle intervention especially important. Screening guidelines are still evolving, but pediatric gastroenterology societies now recommend evaluating children with obesity and metabolic risk markers for liver disease.
Sleep and Liver Fat
An underappreciated contributor to fatty liver is poor sleep. Research has identified an independent association between sleep disorders and fatty liver disease. Sleeping too little or too much, having poor sleep quality, suffering from insomnia, and especially having obstructive sleep apnea all appear to increase the risk of developing or worsening liver steatosis. The intermittent oxygen drops that characterize sleep apnea may be particularly damaging, as they promote oxidative stress and inflammation in liver tissue. Evidence so far points to a one-directional link: disrupted sleep promotes fatty liver rather than the other way around. If you have been diagnosed with steatosis and also struggle with sleep, addressing the sleep problem may be a piece of the treatment puzzle that gets overlooked in a hepatology clinic focused on diet and exercise.
Medications That Can Cause Steatosis
While metabolic factors drive the vast majority of fatty liver cases, certain medications can push fat into the liver on their own. Corticosteroids, tamoxifen, amiodarone, methotrexate, and some antiretroviral drugs used in HIV treatment are among the medications documented to cause or worsen hepatic steatosis. The mechanisms vary: some drugs directly interfere with the liver’s ability to export fat, others disrupt mitochondrial function and impair fat burning, and still others promote insulin resistance as a side effect. If you’ve been told you have fatty liver and you’re on one of these medications, the steatosis may partly be drug-related, though in practice most patients also carry metabolic risk factors that contribute. Stopping the offending drug isn’t always possible, so the clinical conversation usually centers on whether the liver effects are mild enough to tolerate or significant enough to warrant switching to an alternative.